TAIWAN BIO THERAPEUTICS INC.
Update：2023/06/12
Industries
Main Industry
Health Care
Main Product/Service
Leveraging the FAST CGT platform to enhance the specificity, persistence, and stability of regulatory T cells, improving their ability to restore immune tolerance and suppress inflammation as a targeted alternative to non-selective, high-risk immunosuppressants for autoimmune disease treatment and transplant rejection prevention./Utilizing the FAST CGT platform enhance therapeutic efficacy, durability, and precision of MSC therapies for treating inflammatory and ischemic diseases/Integrating cell therapy R&D and clinical applications through the FAST CGT platform to accelerate the development and commercialization
Founded Year
2014
Unified Business No.
24571303
Status
Active
Number of Employees
0
Total Paid-in
Capital
846,050,000 (NT$)
Location of Company
Taiwan
, Hsinchu County
Exit Status
Emerging Stock Exchange(2025)
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, MOE."
Exclusive content for members
Members-only content. Please log in to access.
Introduction
Taiwan Bio is dedicated to driving innovation and expanding access to cell therapies. Through our FAST CGT platform, we reduce costs, enhance efficacy, accelerate development, and streamline production, setting new milestones in the treatment of chronic and immune-related diseases. Originating in Taiwan, our technology is now expanding globally through strategic collaborations with leading U.S. universities and research institutions, fostering a robust cell therapy ecosystem.
